Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics, Bracing & Supports, and accompanying patient care. Headquartered in Iceland, the company employs over 4,000 people located across 36 countries worldwide. Embla Medical has extensive operations in the Americas, Europe, and Asia, as well as distributors in other markets.
Udsigt til en negativ åbning i Europa fra morgenstunden efter fald i Asien og frygt for renteforhøjelser i USA. Derudover fokus regnskaber fra Tesla og Meta. Gæst i studiet her til morgen er CEO Thomas A. E. Andersen fra Danish Aerospace Company, der bl.a. vil tale om selskabet generelt.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Today, Embla Medical’s CEO, Sveinn Sölvason, presented the Q3 2026 results and the key drivers behind them, and outlined the reasoning for the narrowing of the full-year 2026 guidance. The presentation was followed by a Q&A session
Embla Medical will publish its interim report for Q3 2026 on 20 October 2026. At 10:30 CET, CEO Sveinn Sölvason will present the results, comment on the most important developments in the business, and provide an update on the company's outlook for the remainder of 2026, followed by a live online Q&A session.
Udsigt til en negativ åbning i Europa fra morgenstunden efter fald i Asien og uro i Frankrig. Fokus på bl.a. Embla Medical (Q3-regnskab), ALK-Abelló (fase 3-studie i Kina) og Jyske Bank (godkendt opkøb af Formuepleje). Gæst i studiet her til morgen er CEO Michael Hove fra Scandinavian Investment Group, der bl.a. vil tale om Gentoo Medias nye kapitalisering og investeringscase.
ALK-Abelló meldte i går eftermiddags ud, at selskabets fase 3-studie med husstøvmidetabletten ACARIZAX i Kina har nået sit primære endepunkt. Embla Medical er her til morgen ude med regnskabet for Q3 2026.
Udsigt til en svag negativ åbning i Europa fra morgenstunden efter uro i Frankrig. Fokus på bl.a. Lundbeck (ændringer i bestyrelsen). Gæst i studiet her til morgen er Lars Hytting fra Aarthascope, der bl.a. vil tale om DSV.
